Search tips
Search criteria 


Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. 1997 February; 40(2): 228–233.
PMCID: PMC1027054

Reduced bone density in patients with inflammatory bowel disease.


BACKGROUND: Reduced bone mineral density in patients with inflammatory bowel disease is thought to be due to disturbances in calcium homeostasis or the effects of corticosteroid treatment. AIMS: To assess the prevalence and mechanism of reduced bone mineral density in 79 patients with inflammatory bowel disease (44 with Crohn's disease, 35 with ulcerative colitis) who did not have significant risk factors for low bone densities. METHODS: Dual x ray absorptiometry was used to measure bone mineral density and serum and urinary markers of osteoblast (alkaline phosphatase, procollagen 1 carboxy terminal peptide and osteocalcin) and osteoclast (pyridinoline, deoxypyridinoline, and type 1 collagen carboxy terminal peptide) activities to assess bone turnover. RESULTS: There was a high prevalence of low bone mineral density (prevalence of T scores < -1.0 from 51%-77%; T scores < -2.5 (osteoporosis) from 17%-28%) with hips being more often affected than vertebrae (p < 0.001). Reduced bone mineral density did not relate to concurrent or past corticosteroid intake, or type, site, or severity of disease. Whereas calcium homeostasis was normal, bone markers showed increased bone resorption without a compensatory increase in bone formation. CONCLUSIONS: The greater prevalence of reduced hip bone mineral density, as opposed to vertebral, mineral density and the pattern of a selective increase in bone resorption contrasts with that found in other known causes of metabolic bone disease.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Genant HK, Mall JC, Wagonfeld JB, Horst JV, Lanzi LH. Skeletal demineralization and growth retardation in inflammatory bowel disease. Invest Radiol. 1976 Nov-Dec;11(6):541–549. [PubMed]
  • Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987 Apr;28(4):410–415. [PMC free article] [PubMed]
  • Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982 Nov;97(5):699–705. [PubMed]
  • Harries AD, Brown R, Heatley RV, Williams LA, Woodhead S, Rhodes J. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut. 1985 Nov;26(11):1197–1203. [PMC free article] [PubMed]
  • Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut. 1993 Nov;34(11):1543–1546. [PMC free article] [PubMed]
  • Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold C, Frotz S, Gangl A. Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci. 1989 Jul;34(7):1094–1099. [PubMed]
  • Best WR, Becktel JM, Singleton JW, Kern F., Jr Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976 Mar;70(3):439–444. [PubMed]
  • TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. [PMC free article] [PubMed]
  • Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994 Aug;9(8):1137–1141. [PubMed]
  • Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed]
  • Monaghan DA, Power MJ, Fottrell PF. Sandwich enzyme immunoassay of osteocalcin in serum with use of an antibody against human osteocalcin. Clin Chem. 1993 Jun;39(6):942–947. [PubMed]
  • Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy Montbrun T, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992 Sep;37(9):1396–1403. [PubMed]
  • Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, Harris MM. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med. 1991 Oct 24;325(17):1189–1195. [PubMed]
  • Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994 Oct;107(4):1031–1039. [PubMed]
  • Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990 Mar 1;112(5):352–364. [PubMed]
  • Slemenda CW, Hui SL, Longcope C, Johnston CC., Jr Cigarette smoking, obesity, and bone mass. J Bone Miner Res. 1989 Oct;4(5):737–741. [PubMed]
  • Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med. 1994 Feb 10;330(6):387–392. [PubMed]
  • Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteoporos Int. 1993 Jan;3(1):50–52. [PubMed]
  • Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest. 1988 Apr;18(2):191–195. [PubMed]
  • Fiocchi C. Production of inflammatory cytokines in the intestinal lamina propria. Immunol Res. 1991;10(3-4):239–246. [PubMed]
  • Mueller C, Knoflach P, Zielinski CC. T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. Gastroenterology. 1990 Mar;98(3):639–646. [PubMed]
  • Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology. 1992 Feb;102(2):514–519. [PubMed]
  • Duane PD, Teahon K, Crabtree JE, Levi AJ, Heatley RV, Bjarnason I. The relationship between nutritional status and serum soluble interleukin-2 receptor concentrations in patients with Crohn's disease treated with elemental diet. Clin Nutr. 1991 Aug;10(4):222–227. [PubMed]
  • Thomson BM, Saklatvala J, Chambers TJ. Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts. J Exp Med. 1986 Jul 1;164(1):104–112. [PMC free article] [PubMed]
  • Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. Gastroenterology. 1979 Oct;77(4 Pt 2):898–906. [PubMed]

Articles from Gut are provided here courtesy of BMJ Publishing Group